Literature DB >> 16409179

Practice patterns in haemophilia A therapy -- global progress towards optimal care.

S Geraghty1, T Dunkley, C Harrington, K Lindvall, J Maahs, J Sek.   

Abstract

This paper reports the findings of a global survey of practice patterns for the management of patients with haemophilia A. A total of 147 haemophilia treatment centres worldwide responded to the questionnaire, supplying data for 16 115 patients with haemophilia A. From these responses, 38% (range: 25-48%) of patients were under 18 years old. Almost half (47%) of patients were reported to have mild or moderate haemophilia A, 48% had severe haemophilia A (no inhibitor) and 5% were inhibitor patients. Less than half of patients with severe haemophilia A received prophylactic therapy (37%, excluding inhibitor patients) and 54% received on-demand treatment; the remaining 9% were inhibitor patients. Primary prophylaxis rates for severe haemophilia ranged from 73% in Sweden to 17% in the USA. Most respondents (80%) ranked infrequent bleeds as one of the top five reasons for not administering prophylactic treatment, followed by venous access (60%) and cost (45%). Of patients with severe haemophilia (non-inhibitor), 32% on primary prophylaxis and 27% on secondary prophylaxis had indwelling catheters. Risk of infection and the patient's inability to maintain the line were the key concerns cited by nurses relating to venous access. The mean ratio of nurses to patients with haemophilia A was 1:69 and nurses felt that they were either fully (26%) or mostly (45%) autonomous in assessment and treatment decisions. Results from this current survey suggest that worldwide research should be continued so as to improve outcomes through the identification of optimal treatment protocols for the management of haemophilia A.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409179     DOI: 10.1111/j.1365-2516.2006.01189.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  33 in total

Review 1.  Telemedicine and telerehabilitation: current and forthcoming applications in haemophilia.

Authors:  Elena A Boccalandro; Giuseppe Dallari; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2019-02-04       Impact factor: 3.443

2.  "la synoviorthèse" can more than synovitis!

Authors:  Jamshid Farahati
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03       Impact factor: 9.236

Review 3.  Low Dose Prophylaxis in Hemophilia Care.

Authors:  Neeraj Sidharthan; Remya Sudevan
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-15       Impact factor: 0.900

4.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.

Authors:  Takehisa Kitazawa; Tomoyuki Igawa; Zenjiro Sampei; Atsushi Muto; Tetsuo Kojima; Tetsuhiro Soeda; Kazutaka Yoshihashi; Yukiko Okuyama-Nishida; Hiroyuki Saito; Hiroyuki Tsunoda; Tsukasa Suzuki; Hideki Adachi; Taro Miyazaki; Shinya Ishii; Mika Kamata-Sakurai; Takeo Iida; Aya Harada; Keiko Esaki; Miho Funaki; Chifumi Moriyama; Eriko Tanaka; Yasufumi Kikuchi; Tetsuya Wakabayashi; Manabu Wada; Masaaki Goto; Takeshi Toyoda; Atsunori Ueyama; Sachiyo Suzuki; Kenta Haraya; Tatsuhiko Tachibana; Yoshiki Kawabe; Midori Shima; Akira Yoshioka; Kunihiro Hattori
Journal:  Nat Med       Date:  2012-09-30       Impact factor: 53.440

5.  A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.

Authors:  Naoki Uchida; Takehiko Sambe; Koichiro Yoneyama; Naoki Fukazawa; Takehiko Kawanishi; Shinichi Kobayashi; Midori Shima
Journal:  Blood       Date:  2015-12-01       Impact factor: 22.113

Review 6.  Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.

Authors:  Takehisa Kitazawa; Midori Shima
Journal:  Int J Hematol       Date:  2018-10-22       Impact factor: 2.490

Review 7.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

8.  Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project.

Authors:  Elena Santagostino; Maria Messina; Annarita Tagliaferri; Alfonso Iorio; Massimo Morfini
Journal:  Blood Transfus       Date:  2013-01-23       Impact factor: 3.443

9.  New treatments in hemophilia: insights for the clinician.

Authors:  Karin Knobe; Erik Berntorp
Journal:  Ther Adv Hematol       Date:  2012-06

Review 10.  BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review.

Authors:  Johnny N Mahlangu; Sanjay P Ahuja; Jerzy Windyga; Nikki Church; Anita Shah; Lawrence Schwartz
Journal:  Ther Adv Hematol       Date:  2018-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.